Parafibromin immunoreactivity: Its use as an additional diagnostic marker for parathyroid tumor classification

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 501-512

  Juhlin, C C ^a   Villablanca, A ^a   Sandelin, K ^a   Haglund, F ^a   Nordenstrom J ^a   Forsberg, L ^a   Branstrom R ^a   Obara, T ^b   Arnold, A ^c   Larsson, C ^a   Hoog A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Endocrine Surgery ^*  (Japan)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PRAFIBROMIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HRPT2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PARATHYROID TUMOR; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34547812591     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0021     Document Type: Article

References (36)

1. Bondeson L, Sandelin K & Grimelius L 1993 Histopathological variables and DNA cytometry in parathyroid carcinoma. American Journal of Surgical Pathology 17 820-829.
2. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
3. Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE, Laidler P, Manek S, Robbins CM, Salti IS et al. 2005 Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. Journal of Internal Medicine 257 18-26.
4. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N et al. 2006 Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Journal of Clinical Endocrinology 64 299-306.
5. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY, Thakker RV 2007 Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26 1213-1221.
6. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD et al. 2002 HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumour syndrome. Nature Genetics 32 676-680.
7. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P et al. 2004 Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. Journal of Clinical Endocrinology and Metabolism 89 5583-5591.
8. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF & Arnold A 1994 Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New England Journal of Medicine 330 757-761.
9. DeLellis RA 2005 Parathyroid carcinoma - an overview. Advances in Anatomic Pathology 12 53-61.
10. DeLellis RA, Lloyd RV, Heitz PU & Eng C 2004 Tumours of endocrine organs. In World Health Organization Classification of Tumour Pathology and Genetics, Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press.
11. Kip1 protein. American Journal of Surgical Pathology 23 288-295.
12. Farnebo F, Auer G, Farnebo L-O, The BT, Twigg S, Apendblad U, Thomson NW, Grimelius L, Larsson C & Sandelin K 1999 Evaluation of retinoblastoma and Ki-67 as diagnostic markers in benign and malignant parathyroid disease. World Journal of Surgery 23 68-74.
13. Forsberg L, Larsson C, Sofiadis A, Lewensohn R, Höög A & Lehtio J 2006 Pre-fractionation of archival frozen tumours for proteomics applications. Journal of Biotechnology 126 582-586.
14. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM & Marsh DJ 2006 Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. American Journal of Surgical Pathology 30 1140-1149.
15. Gimm O, Lorenz K, Nguyen Thanh P, Schneyer U, Howell VM, Marsh DJ, Teh BT, Krause U & Dralle H 2006 Prophylactic parathyroidectomy for familial parathyroid carcinoma. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen 77 15-24 (In German).
16. Grimelius L & Johansson H 1997 Pathology of parathyroid tumors. International Seminars in Surgical Oncology 13 142-154.
17. Hahn MA & Marsh DJ 2005 Identification of a functional bipartite nuclear localization in the tumor suppressor parafibromin. Oncogene 24 6241-6248.
18. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J et al. 2003 HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics 40 657-663.
19. Juhlin C, Höög A, Yakoleva T, Leibiger I, Leibiger B, Weber G, Larsson C & Villablanca A 2006 Loss of parafibromin expression in a subset of sporadic parathyroid adenomas. Endocrine Related Cancer 13 509-523.
20. Krebs LJ, Shattuck TM & Arnold A 2005 HRPT2 mutational analysis of typical sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 90 5015-5017.
21. Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, Farnebo L-O, Sandelin K & Larsson C 2000 Patterns of chromosomal imbalances in parathyroid carcinomas. American Journal of Pathology 157 579-586.
22. Levin KE, Galante M & Clark OH 1987 Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 101 649-660.
23. Mittendorf EA & McHenry CR 2005 Parathyroid carcinoma. Journal of Surgical Oncology 89 136-142.
24. Mosimann C, Hausmann G & Basler K 2006 Parafibromin/ Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell 125 327-341.
25. Polak J & van Noorden S (1986) An introduction to immunocytochemistry: current techniques and problems. In Immunocytochemistry: Modern Methods and Applications, edn 2. Bristol: John Wright & Sons.
26. Rodgers SE & Perrier ND 2006 Parathyroid carcinoma. Current Opinion in Oncology 18 16-22.
27. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH & Meyerson M 2005 The parafibromin tumor suppressor protein is part of a human Paf1 complex. Molecular and Cellular Biology 25 612-620.
28. Sandelin K, Auer G, Bondeson L, Grimelius L & Farnebo L-O 1992 Prognostic factors in parathyroid cancer: a review of 95 cases. World Journal of Surgery 16 724-731.
29. Shane E 2001 Clinical review 122: parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 485-193.
30. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD et al. 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine 349 1722-1729.
31. Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, Brennan MF, Singh B & Ghossein RA 2003 Parathyroid neoplasms: clinical, histopathological and tissue microarray-based molecular analysis. Human Pathology 34 54-64.
32. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR et al. 2004 Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clinical Cancer Research 10 6629-6637.
33. Vasef MA, Brynes RK, Sturm M, Bromley C & Robinson RA 1999 Expression of cyclin D1 in parathyroid carcinomas, adenomas and hyperplasias: a Paraffin Immunohistochemical study. Modern Pathology 12 412-416.
34. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ & Simonds WF 2005 Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24 1272-1276.
35. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D & Krek W 2005 The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Molecular and Cellular Biology 25 5052-5060.
36. Zhang C, Kong D, Tan MH, Pappas DL Jr, Wang PF, Chen J, Farber J, Zhang N, Koo HM, Weinreich M et al. 2006 Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochemical and Biophysical Research Communications 350 17-24.